ALP Bio combines human immune organoids with generative AI to reduce the immunogenicity risk of therapeutic antibodies. The Schlieren-based company has raised CHF 1.75 million in pre-seed funding, led by 42CAP.
- Announced on
- Round
- Pre-seed
- Amount
- CHF 1.8 M
- Location
- Schlieren, canton of Zurich
- Sector
- Biotech & life sciences
Investors
- 42CAP lead
- Ajira Ventures
- Venture Kick
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic